Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

What is the optimal treatment for patients with RA who fail to respond to monotherapy with methotrexate?

Nature Clinical Practice Rheumatology volume 4, pages 346–347 (2008)Cite this article

boxed-textvan der Kooij SM et al. (2007) Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 66: 1356–1362

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Combe B et al. (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66: 34–45

    Article  CAS  Google Scholar 

  2. Braun J et al. (2008) Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 58: 73–81

    Article  CAS  Google Scholar 

  3. van der Heijde D et al. (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54: 1063–1074

    Article  CAS  Google Scholar 

  4. Schiff M et al. (2007) Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: a phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis [10.1136/ard.2007.080002]

  5. van Riel PL et al. (2006) Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 65: 1478–1483

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Helen Jaques, Editorial Assistant, Nature Clinical Practice.

Author information

Author notes

  1. Hôpital Notre-Dame, Rheumatic Disease Unit, 1560 Sherbrooke Est, Montreal, Quebec H2L 4M1, Canada paulharaoui@attglobal.net

Authors and Affiliations

  1. B Haraoui is a Clinical Associate Professor of Medicine at the Université de Montréal and Head of the Clinical Research Unit in Rheumatology at the Centre Hospitalier de l'Université de Montréal (CHUM, Hôpital Notre-Dame), Quebec, Canada.,

    Boulos Haraoui

Authors
  1. Boulos Haraoui
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author has received speakers' honoraria, been a consultant for and received grant/research support from the following companies: Abbott, Amgen, Bristol–Myers Squibb, Roche, Schering and Wyeth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haraoui, B. What is the optimal treatment for patients with RA who fail to respond to monotherapy with methotrexate?. Nat Rev Rheumatol 4, 346–347 (2008). https://doi.org/10.1038/ncprheum0830

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0830

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing